Catalent to Ramp Up J&J Vaccine Production at Italian Plant

New Jersey-based drugmaker Catalent has announced that it will significantly scale up manufacturing of the Johnson & Johnson (J&J) COVID-19 vaccine at its 300,000 square-foot facility in Anagni, Italy, which should help accelerate much-needed vaccine distribution in Europe.

Under an expanded partnership, Catalent will provide vial-filling, inspection, labeling and packing services at the plant, adding a new high-speed vial-filling line that is expected to be operational at the end of this year to support production through the end of 2022.

Catalent’s facility in Bloomington, Ind., has been conducting manufacturing and packaging services for the J&J vaccine for distribution in the U.S.